NOKOMIS, Fla.--(BUSINESS WIRE)--According to a recent report from GBI Research, Strategic partnerships between pharmaceutical companies and stem cell research companies have been given a boost in stem cell R&D, and Rainbow Biosciences, a division of Rainbow Coral Corp. (OTCBB:RBCC) is positioning itself to capitalize.
“Strategic partnerships between pharmaceutical companies and stem cell research companies has given a big boost to stem cell R&D,” Brown said. “A lot of development money is going to be flowing into this sector in the coming years, and n3D can help position RBCC to build significant market share in a booming industry.”
With major pharmaceutical companies looking to launch new therapies in the marketplace, there has been a spur in investments from these companies into stem cell research through strategic partnerships with stem cell research companies. In order to capitalize on this trend, RBCC announced this week that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc. (n3D). N3D has developed a proprietary process that enables scientists to grow cells in a three dimensional environment, a major advantage in creating effective stem cell treatments.
For more information on Rainbow BioSciences, RBCC’s biotechnology division, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ:CTIC), Abbott Laboratories (NYSE:ABT) Affymax, Inc. (NASDAQ:AFFY), and Celgene Corp. (NASDAQ:CELG).
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.